Etranacogene dezaparvovec (Hemgenix, CSL Behring) has a conditional marketing authorisation 'for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors'.
The dosage schedule is available in the summary of product characteristics for etranacogene dezaparvovec.
The list price per treatment for a single dose of etranacogene dezaparvovec is £2,600,000.
The company has a commercial arrangement. This makes etranacogene dezaparvovec available to the NHS with a discount. The size of the discount is commercial in confidence.